These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Neurofilaments as biomarkers in multiple sclerosis. Teunissen CE; Khalil M Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131 [TBL] [Abstract][Full Text] [Related]
28. Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis. Sellner J; Davies NW; Howard RS; Petzold A Eur J Neurol; 2014 Jun; 21(6):845-50. PubMed ID: 24684186 [TBL] [Abstract][Full Text] [Related]
29. Clinical and MRI correlates of CSF neurofilament light chain levels in relapsing and progressive MS. Damasceno A; Dias-Carneiro RPC; Moraes AS; Boldrini VO; Quintiliano RPS; da Silva VAPG; Farias AS; Brandão CO; Damasceno BP; Dos Santos LMB; Cendes F Mult Scler Relat Disord; 2019 May; 30():149-153. PubMed ID: 30772673 [TBL] [Abstract][Full Text] [Related]
31. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Pijnenburg YA; Janssen JC; Schoonenboom NS; Petzold A; Mulder C; Stigbrand T; Norgren N; Heijst H; Hack CE; Scheltens P; Teunissen CE Dement Geriatr Cogn Disord; 2007; 23(4):225-30. PubMed ID: 17290105 [TBL] [Abstract][Full Text] [Related]
32. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Peng L; Bi C; Xia D; Mao L; Qian H Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578 [TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. Martin SJ; McGlasson S; Hunt D; Overell J J Neurol Neurosurg Psychiatry; 2019 Sep; 90(9):1059-1067. PubMed ID: 31123141 [TBL] [Abstract][Full Text] [Related]
34. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J Mult Scler; 2017 Jan; 23(1):62-71. PubMed ID: 27003946 [TBL] [Abstract][Full Text] [Related]
36. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment. Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559 [TBL] [Abstract][Full Text] [Related]
37. High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. van der Vuurst de Vries RM; Wong YYM; Mescheriakova JY; van Pelt ED; Runia TF; Jafari N; Siepman TA; Melief MJ; Wierenga-Wolf AF; van Luijn MM; Samijn JP; Neuteboom RF; Hintzen RQ Mult Scler; 2019 Jun; 25(7):958-967. PubMed ID: 29774770 [TBL] [Abstract][Full Text] [Related]